Immunitybio Inc experienced a notable rise in stock price, reflecting growing investor confidence.
Immunitybio Inc (NASDAQ:IBRX) went up yesterday by 6.91%, closing the trading session at CA$9.44. This positive movement was driven by strong market sentiment and insights from investment analysts.
Advertisement
Immunitybio Inc
IBRX.US
IBRX.US
Immunitybio Inc
WealthAwesomeMarket cap
$9.36B
52W high
$12.43
52W low
$1.95
1W change
+9.39%
Beta
0.14
Analyst Price Targets
Based on 5 analysts covering IBRX · as of Sep 17, 2026
Wall Street analysts forecast IBRX stock price to rise 35.1% over the next 12 months.
Consensus
Strong Buy4.60 / 5.00
Avg. Target
C$12.75
+35.1% Upside
Current Price
C$9.44
Last close
Analyst Breakdown (5 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on IBRX's historical volatility
30-Day Vol
64.0%
Annualized
90-Day Vol
64.3%
Annualized
Trend (90d)
+31.4%
Annualized drift
90d Mean
C$10.56
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.80 | C$7.86 – C$12.22 |
| 60 trading days | C$10.17 | C$7.45 – C$13.90 |
| 90 trading days | C$10.56 | C$7.21 – C$15.48 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are increasingly optimistic about Immunitybio's potential in the oncology market, especially after recent endorsements from investment funds that highlight its growth prospects.
Immunitybio's stock has surged 256.05% over the past year.
Advertisement
This substantial year-over-year increase shows that the market recognizes Immunitybio's innovative therapies and their potential impact on cancer treatment.
Bull case
Immunitybio's innovative immunotherapies, especially Anktiva, are well-positioned to capture a significant share of the emerging $5.8 billion cancer treatment market. As regulatory approvals progress, there’s potential for further expansion.
Bear case
Despite the positive momentum, investors should remain cautious. Market volatility and the competitive landscape in the biotech sector could impact future performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
